GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biofrontera B8FK.DE · EUR

Health Care · XETRA · 🇩🇪 Germany

Compare

2.94

-2.65%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Biofrontera — daily XETR:B8FK End of day
Market value
€17.9m
Last close × shares
Volume
13
Shares, 9 Nov 2026

About Biofrontera

Its shares trade on XETRA under the ticker B8FK.DE. It has been listed since 30 October 2006. In the fiscal year to 31 December 2025, it reported revenue of €13.2m and a net loss of €4.0m. At that date it held total assets of €20.6m and shareholders' equity of €14.9m.

Biofrontera AG operates as a biopharmaceutical company, which engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. The company is headquartered in Leverkusen, Nordrhein-Westfalen. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Figures and description from our data supplier, not checked against the company's own report.

More about Biofrontera →

Latest on Biofrontera

Our reporting

We have not reported on Biofrontera yet.

Next results

19 Nov 2026

Due on 19 Nov 2026. Analysts expect earnings of -1.10 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Biofrontera's ticker?

Biofrontera trades as B8FK.DE on XETRA, under ISIN DE000A4BGGM7.

What was Biofrontera's last closing price?

2.94 on 9 Nov 2026. The figure is in EUR and is never converted.

When does Biofrontera next report results?

Results are expected on 19 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.